#1 Clinical Trials Search in Europe

Ceftolozane

Ceftolozane is an emerging antibiotic that shows great potential in treating serious bacterial infections, particularly those caused by drug-resistant organisms. This article summarizes key findings from clinical trials investigating the use of ceftolozane, often combined with tazobactam, for various conditions including pneumonia, cystic fibrosis exacerbations, and infections in critically ill patients.

Table of Contents

What is Ceftolozane?

Ceftolozane is a new type of antibiotic that is often combined with another drug called tazobactam. This combination is known as ceftolozane-tazobactam or ceftolozane/tazobactam. It’s also sold under the brand name Zerbaxa[1]. Ceftolozane belongs to a class of antibiotics called cephalosporins, which are used to treat various bacterial infections[2].

What Conditions Does Ceftolozane Treat?

Ceftolozane-tazobactam is used to treat several types of serious bacterial infections, including:

  • Complicated urinary tract infections (cUTI): These are infections in the urinary system that are more difficult to treat than typical urinary tract infections[3].
  • Complicated intra-abdominal infections (cIAI): These are infections that occur inside the abdomen and are more severe or complex[3].
  • Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP): These are types of lung infections that patients can get while in the hospital, especially if they’re on a breathing machine[4].
  • Infections caused by Pseudomonas aeruginosa: This is a type of bacteria that can cause severe infections and is often resistant to many antibiotics[5].

How Does Ceftolozane Work?

Ceftolozane works by stopping bacteria from building their cell walls, which they need to survive and multiply. When combined with tazobactam, it becomes even more effective. Tazobactam helps protect ceftolozane from being broken down by certain enzymes that some bacteria produce to resist antibiotics[2].

One of the key benefits of ceftolozane-tazobactam is its effectiveness against bacteria that have become resistant to other antibiotics. It’s particularly useful against a type of bacteria called Pseudomonas aeruginosa, which is known for being hard to treat[6].

How is Ceftolozane Administered?

Ceftolozane-tazobactam is given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The typical dose for adults is 1.5 grams (1 gram of ceftolozane and 0.5 grams of tazobactam) given every 8 hours. For more severe infections like hospital-acquired pneumonia, the dose may be increased to 3 grams every 8 hours[2].

The infusion usually takes about an hour. The length of treatment can vary depending on the type and severity of the infection, but it’s typically between 4 to 14 days[5].

Effectiveness of Ceftolozane

Clinical trials have shown that ceftolozane-tazobactam is effective in treating various types of infections. It has been particularly successful in treating infections caused by bacteria that are resistant to other antibiotics[6].

For example, in patients with cystic fibrosis who often suffer from lung infections caused by resistant bacteria, ceftolozane-tazobactam has shown promising results[1]. It’s also been effective in treating complicated urinary tract and intra-abdominal infections caused by certain types of resistant bacteria[3].

Ongoing Research and Clinical Trials

Researchers are continually studying ceftolozane-tazobactam to better understand its effectiveness and safety in different patient groups and for various types of infections. Some ongoing areas of research include:

  • Its use in treating infections in patients with blood cancers[5].
  • Its effectiveness against certain types of resistant bacteria in critically ill patients[4].
  • How well it works compared to other antibiotics for bloodstream infections[3].
  • How the drug moves through the body in different patient groups, such as those with burns or brain injuries[7][8].

Potential Side Effects

Like all medications, ceftolozane-tazobactam can cause side effects. Common side effects may include:

  • Nausea
  • Diarrhea
  • Headache
  • Fever
  • Constipation

More serious side effects, although rare, can include severe allergic reactions, kidney problems, or a type of diarrhea caused by C. difficile bacteria. It’s important to tell your doctor about any side effects you experience[5].

Remember, your doctor has prescribed this medication because they believe the benefits outweigh the potential risks. Always follow your doctor’s instructions and don’t hesitate to ask questions if you have concerns about your treatment.

Aspect Details
Drug Name Ceftolozane (often combined with Tazobactam)
Drug Class Cephalosporin antibiotic
Main Target Multidrug-resistant Pseudomonas aeruginosa infections
Administration Intravenous infusion, typically every 8 hours
Key Indications Hospital-acquired pneumonia, ventilator-associated pneumonia, complicated urinary tract infections, intra-abdominal infections
Special Populations Being studied in cystic fibrosis patients and critically ill patients
Safety Profile Generally well-tolerated; common side effects include nausea, diarrhea, headache
Ongoing Research Optimal dosing, effectiveness against resistant bacteria, use in special populations (e.g., cystic fibrosis)

FAQ

  • What is ceftolozane and how does it work? Ceftolozane is a new antibiotic that belongs to the cephalosporin class. It is often combined with tazobactam, which is a beta-lactamase inhibitor. Together, they work to fight bacterial infections, especially those caused by drug-resistant organisms like Pseudomonas aeruginosa.
  • What types of infections can ceftolozane treat? Clinical trials are investigating ceftolozane for treating various serious infections, including hospital-acquired and ventilator-associated pneumonia, complicated urinary tract infections, intra-abdominal infections, and lung infections in people with cystic fibrosis.
  • How is ceftolozane administered? Ceftolozane is given intravenously (through a vein). The exact dose and frequency can vary depending on the type and severity of infection, but it's often given every 8 hours.
  • Are there any side effects associated with ceftolozane? Like all antibiotics, ceftolozane can have side effects. Common ones may include nausea, diarrhea, headache, and fever. Serious side effects are rare but can include allergic reactions. Clinical trials are closely monitoring for any adverse events.
  • How effective is ceftolozane against drug-resistant bacteria? Early clinical trial results suggest that ceftolozane is effective against many drug-resistant bacteria, particularly Pseudomonas aeruginosa. It's being studied as a potential treatment option for infections that don't respond to other antibiotics.

Ongoing Clinical Trials on Ceftolozane

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study Comparing Different Antibiotic Treatments for ICU Patients with Hospital-Acquired Sepsis: Focus on Cefepime and Drug Combination

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety of Ceftolozane and Tazobactam for Children with Hospital-Acquired Pneumonia

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Estonia Greece Spain

  • Study on Avibactam and Drug Combination for Treating Severe Infections in Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

Glossary

  • Ceftolozane: A new antibiotic belonging to the cephalosporin class, often combined with tazobactam to treat serious bacterial infections.
  • Tazobactam: A beta-lactamase inhibitor that is combined with ceftolozane to enhance its effectiveness against certain bacteria.
  • Pseudomonas aeruginosa: A type of bacteria that can cause serious infections, especially in hospitalized patients, and is often resistant to many antibiotics.
  • Ventilator-associated pneumonia: A lung infection that develops in people who are on mechanical ventilation breathing machines in hospitals.
  • Cystic fibrosis: A genetic disorder that affects mostly the lungs, causing recurrent infections and breathing problems.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Minimum Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.
  • Multidrug-resistant (MDR): Bacteria that are resistant to multiple types of antibiotics.
  • Extensively drug-resistant (XDR): Bacteria that are resistant to almost all available antibiotics.
  • Nosocomial infection: An infection acquired in a hospital setting, typically 48 hours or more after admission.

References

  1. https://clinicaltrials.gov/study/NCT02421120
  2. https://clinicaltrials.gov/study/NCT04257812
  3. https://clinicaltrials.gov/study/NCT04238390
  4. https://clinicaltrials.gov/study/NCT04352855
  5. https://clinicaltrials.gov/study/NCT04673175
  6. https://clinicaltrials.gov/study/NCT03510351
  7. https://clinicaltrials.gov/study/NCT03002506
  8. https://clinicaltrials.gov/study/NCT03309657